Co-Authors
This is a "connection" page, showing publications co-authored by Susan L. Cohn and Mark Applebaum.
Connection Strength
6.486
-
5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. Clin Cancer Res. 2020 03 15; 26(6):1309-1317.
Score: 0.711
-
5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. JCO Precis Oncol. 2019; 3.
Score: 0.682
-
Emerging and investigational therapies for neuroblastoma. Expert Opin Orphan Drugs. 2017; 5(4):355-368.
Score: 0.587
-
Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget. 2016 Nov 22; 7(47):76816-76826.
Score: 0.574
-
Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan; 62(1):128-33.
Score: 0.494
-
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. NPJ Precis Oncol. 2024 Nov 08; 8(1):255.
Score: 0.249
-
Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures. Cancer Res Commun. 2024 Aug 01; 4(8):2255-2266.
Score: 0.245
-
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. Res Sq. 2024 Jun 04.
Score: 0.242
-
Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. Cell Rep. 2024 May 28; 43(5):114165.
Score: 0.240
-
Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. Pediatr Blood Cancer. 2024 Jan; 71(1):e30735.
Score: 0.232
-
Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. bioRxiv. 2023 Sep 01.
Score: 0.230
-
T-cell inflammation is prognostic of survival in patients with high-risk neuroblastoma enriched for an adrenergic signature. bioRxiv. 2023 Jun 28.
Score: 0.227
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
Score: 0.211
-
Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clin Cancer Inform. 2021 12; 5:1181-1188.
Score: 0.203
-
Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248.
Score: 0.198
-
Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients. Pediatr Blood Cancer. 2020 10; 67(10):e28390.
Score: 0.185
-
Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther. 2019 03; 18(3):507-516.
Score: 0.167
-
Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. J Natl Cancer Inst. 2017 10 01; 109(10).
Score: 0.152
-
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185.
Score: 0.145
-
Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids. Oncotarget. 2016 Nov 22; 7(47):77696-77706.
Score: 0.144
-
Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17.
Score: 0.132
-
Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma over Two Decades. EJC Paediatr Oncol. 2023 Dec; 2.
Score: 0.057
-
MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. Epigenetics. 2022 12; 17(13):2056-2074.
Score: 0.053
-
Reply to K. Beiske et al. J Clin Oncol. 2020 11 01; 38(31):3720-3721.
Score: 0.047
-
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 06 10; 38(17):1906-1918.
Score: 0.045
-
Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. Pediatr Blood Cancer. 2016 Jun; 63(6):1019-23.
Score: 0.034